Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel

INTRODUCTION: Natural health products (NHPs) include complementary/alternative medicines, dietary supplements, nutraceuticals, and traditional medicines. Natural health products are often self-prescribed and used alongside conventional medicines, raising safety concerns. AIMS: This study aims to explore NHP-conventional medicine (NHP-drug) combinations used by respondents in New Zealand (NZ), identify those with the potential to cause NHP-drug interactions, and assesses the feasibility of coding NHPs using the WHODrug dictionary. METHODS: A dataset from a pilot study on NHP use in NZ was analysed. Data on NHP and conventional medicine use were descriptively analysed. Where possible, specific product ingredient lists were verified. Two coders independently assigned WHODrug Global codes to each NHP and conventional medicine. Fleiss' Kappa measured inter-coder agreement. RESULTS: Of 992 participants, 381 (38.4%) were current NHP users, reporting 1-18 NHPs. Among them, 271 (71.1%) used conventional medicines concurrently. Natural health product-drug combinations with potential interactions were found with fish oil, coenzyme Q10, turmeric, and glucosamine. An interaction involving fish oil and warfarin was rated as 'may result in significant hazard.' One-third (33.1%) of NHPs could not be coded using WHODrug. Codability agreement was higher for conventional medicines (93.7%) than for NHPs (63.5%). Fleiss' Kappa indicated moderate agreement for NHPs (κ = 0.576) and very good agreement for conventional medicines (κ = 0.911). CONCLUSION: Substantial concurrent NHP-drug use was identified, including combinations with potential adverse reactions. A larger, nationally representative dataset on NHP exposures in NZ is needed. Current challenges in coding NHPs highlight the need for standardised, comprehensive coding tools in future research for comprehensive analysis.

Authors

Institutions

Publication Details

Journal
Drug Safety
Published
2026-05-09
DOI
https://doi.org/10.1007/s40264-026-01667-5
Primary Topic
Complementary and Alternative Medicine Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel

Joanne Barnes, Jeff Harrison, Sofia Su Ye, E Lyn Lee et al.
Drug Safety
Complementary and Alternative Medicine Studies
article

Assessing Natural Health Product-Drug Interactions and Coding Feasibility: Analysis of a New Zealand General Population Dataset from an Online Market Research Panel

Joanne Barnes, Jeff Harrison, Sofia Su Ye, E Lyn Lee, Fraser Ogle, Jyadeep Nagra
article en

Abstract

INTRODUCTION: Natural health products (NHPs) include complementary/alternative medicines, dietary supplements, nutraceuticals, and traditional medicines. Natural health products are often self-prescribed and used alongside conventional medicines, raising safety concerns. AIMS: This study aims to explore NHP-conventional medicine (NHP-drug) combinations used by respondents in New Zealand (NZ), identify those with the potential to cause NHP-drug interactions, and assesses the feasibility of coding NHPs using the WHODrug dictionary. METHODS: A dataset from a pilot study on NHP use in NZ was analysed. Data on NHP and conventional medicine use were descriptively analysed. Where possible, specific product ingredient lists were verified. Two coders independently assigned WHODrug Global codes to each NHP and conventional medicine. Fleiss' Kappa measured inter-coder agreement. RESULTS: Of 992 participants, 381 (38.4%) were current NHP users, reporting 1-18 NHPs. Among them, 271 (71.1%) used conventional medicines concurrently. Natural health product-drug combinations with potential interactions were found with fish oil, coenzyme Q10, turmeric, and glucosamine. An interaction involving fish oil and warfarin was rated as 'may result in significant hazard.' One-third (33.1%) of NHPs could not be coded using WHODrug. Codability agreement was higher for conventional medicines (93.7%) than for NHPs (63.5%). Fleiss' Kappa indicated moderate agreement for NHPs (κ = 0.576) and very good agreement for conventional medicines (κ = 0.911). CONCLUSION: Substantial concurrent NHP-drug use was identified, including combinations with potential adverse reactions. A larger, nationally representative dataset on NHP exposures in NZ is needed. Current challenges in coding NHPs highlight the need for standardised, comprehensive coding tools in future research for comprehensive analysis.

Drug Safety
University of Auckland (NZ)
University of Auckland, Health Research Council of New Zealand
Openalex Percentile: Top 4%
Complementary and Alternative Medicine Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.